Golimumab for the Treatment of Ulcerative Colitis

Overview

Journal Expert Opin Biol Ther

Specialties Biology
Pharmacology

Date 2017 May 5

PMID 28472597

Citations 15

Authors

Mathurin Flamant

Stephane Paul

Xavier Roblin

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor antagonists have revolutionized the therapeutic management of inflammatory bowel disease. Infliximab and adalimumab were the first biological agents used to induce and maintain remission in ulcerative colitis. More recently, a third tumor necrosis factor antagonist, golimumab, was approved, extending the therapeutic approach for moderate-to-severe ulcerative colitis. Areas covered: In this review, the authors review the literature on the efficacy and safety of golimumab in the context of other anti-TNF agents used in the treatment of this disease. The role of therapeutic drug monitoring in the case of loss of response to an anti-TNF agent is also discussed. Expert opinion: Golimumab is currently effective to induce and maintain remission in patients with ulcerative colitis, especially those patients who are naive for an anti-TNF agent. No large studies have evaluated the efficacy of golimumab after failure of a first-line TNF antagonist therapy. In the case of loss of response to a first anti-TNF agent, therapeutic drug monitoring is essential to determine the most suitable therapeutic option.

Citing Articles

Case report: Ulcerative colitis-related spondyloarthritis treated with golimumab until 27 weeks of gestation.

Okazaki R, Hirata I, Ikegami H, Rokutanda R, Funakoshi R Obstet Med. 2024; :1753495X241297559.

PMID: 39605871 PMC: 11590078. DOI: 10.1177/1753495X241297559.

Structure and regulatory mechanisms of food-derived peptides in inflammatory bowel disease: A review.

Qiu W, Wang Z, Liu Q, Du Q, Zeng X, Wu Z Food Sci Nutr. 2024; 12(9):6055-6069.

PMID: 39554349 PMC: 11561845. DOI: 10.1002/fsn3.4228.

Attenuation of Chronic Inflammation in Intestinal Organoids with Graphene Oxide-Mediated Tumor Necrosis Factor-α_Small Interfering RNA Delivery.

Sakib S, Zou S Langmuir. 2024; .

PMID: 38325360 PMC: 10883062. DOI: 10.1021/acs.langmuir.3c02741.

Therapeutic Antibodies in Medicine.

Sharma P, Joshi R, Pritchard R, Xu K, Eicher M Molecules. 2023; 28(18).

PMID: 37764213 PMC: 10535987. DOI: 10.3390/molecules28186438.

Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.

Goll R, Moe O, Johnsen K, Meyer R, Friestad J, Gundersen M BMC Gastroenterol. 2022; 22(1):464.

PMID: 36384462 PMC: 9670620. DOI: 10.1186/s12876-022-02559-5.

References

Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B . Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015; 80(4):727-39. PMC: 4594709. DOI: 10.1111/bcp.12642. View

Detrez I, Dreesen E, Van Stappen T, de Vries A, Brouwers E, Van Assche G . Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis. J Crohns Colitis. 2016; 10(5):575-81. PMC: 4957447. DOI: 10.1093/ecco-jcc/jjv241. View

Reinisch W, Sandborn W, Hommes D, DHaens G, Hanauer S, Schreiber S . Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011; 60(6):780-7. DOI: 10.1136/gut.2010.221127. View

Stidham R, Lee T, Higgins P, Deshpande A, Sussman D, Singal A . Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis. Aliment Pharmacol Ther. 2014; 39(7):660-71. PMC: 6979320. DOI: 10.1111/apt.12644. View

Ungar B, Kopylov U, Engel T, Yavzori M, Fudim E, Picard O . Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab. Aliment Pharmacol Ther. 2016; 45(2):276-282. DOI: 10.1111/apt.13862. View

Lichtenstein G, Diamond R, Wagner C, Fasanmade A, Olson A, Marano C . Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009; 30(3):210-26. DOI: 10.1111/j.1365-2036.2009.04027.x. View

Feagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W . Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013; 369(8):699-710. DOI: 10.1056/NEJMoa1215734. View

Sandborn W, Feagan B, Marano C, Zhang H, Strauss R, Johanns J . Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2013; 146(1):85-95. DOI: 10.1053/j.gastro.2013.05.048. View

Gibson P, Feagan B, Sandborn W, Marano C, Strauss R, Johanns J . Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016; 7:e168. PMC: 4855165. DOI: 10.1038/ctg.2016.24. View

10.

Shealy D, Cai A, Staquet K, Baker A, Lacy E, Johns L . Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010; 2(4):428-39. PMC: 3180089. DOI: 10.4161/mabs.12304. View

11.

Bendtzen K, Ainsworth M, Steenholdt C, Thomsen O, Brynskov J . Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009; 44(7):774-81. DOI: 10.1080/00365520802699278. View

12.

Kay J, Fleischmann R, Keystone E, Hsia E, Hsu B, Zhou Y . Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Rheumatol. 2016; 43(12):2120-2130. DOI: 10.3899/jrheum.160420. View

13.

Rutgeerts P, Sandborn W, Feagan B, Reinisch W, Olson A, Johanns J . Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353(23):2462-76. DOI: 10.1056/NEJMoa050516. View

14.

Androulakis I, Zavos C, Christopoulos P, Mastorakos G, Gazouli M . Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease. World J Gastroenterol. 2015; 21(47):13205-11. PMC: 4679752. DOI: 10.3748/wjg.v21.i47.13205. View

15.

Coskun M, Vermeire S, Nielsen O . Novel Targeted Therapies for Inflammatory Bowel Disease. Trends Pharmacol Sci. 2016; 38(2):127-142. DOI: 10.1016/j.tips.2016.10.014. View

16.

DHaens G, Sandborn W, Feagan B, Geboes K, Hanauer S, Irvine E . A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007; 132(2):763-86. DOI: 10.1053/j.gastro.2006.12.038. View

17.

Rutgeerts P, Feagan B, Marano C, Padgett L, Strauss R, Johanns J . Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015; 42(5):504-14. PMC: 4755132. DOI: 10.1111/apt.13291. View

18.

Kay J, Matteson E, Dasgupta B, Nash P, Durez P, Hall S . Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum. 2008; 58(4):964-75. DOI: 10.1002/art.23383. View

19.

Singh S, Garg S, Wang Z, Murad M, Loftus Jr E . Letter: comparative efficacy of biological therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2014; 39(12):1432-3. DOI: 10.1111/apt.12760. View

20.

Kawalec P, Pilc A . An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis. Arch Med Sci. 2016; 12(5):1097-1109. PMC: 5016577. DOI: 10.5114/aoms.2016.58682. View